Cyclacel Pharmaceuticals (CYCC) 3.28 $CYCC
Cyclacel Pharmaceuticals concludes offering of USD10m of common shares
M2 - Thu Apr 10, 7:01AM CDT
US-based biopharmaceutical company Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) revealed on Wednesday the completion of its offering of 2,857,143 shares of its common stock.
Independent Investigators Present Non-Clinical Data Providing Rationale for Sapacitabine Combination Treatment With Bcr-Abl Inhibitors in CML
GlobeNewswire - Thu Apr 10, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that independent investigators reported non-clinical data supporting the combination potential of Cyclacel's oral sapacitabine with Bcr-Abl inhibitors, including imatinib and ponatinib, in chronic myeloid leukemia (CML) cell lines. The data were reported in a poster presentation at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) held April 5-9, 2014 in San Diego.
Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering
GlobeNewswire - Wed Apr 09, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced that it has closed the previously announced underwritten offering of 2,857,143 shares of its common stock at a price to the public of $3.50 per share for gross proceeds of approximately $10.0 million. In addition, the Company has granted the underwriters a 30-day option to purchase an additional 428,571 shares of common stock to cover over-allotments, if any.
Cyclacel Pharmaceuticals Announces $10 Million Underwritten Offering
GlobeNewswire - Fri Apr 04, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced the pricing of an underwritten public offering of 2,857,143 shares of its common stock to institutional and other investors at a price to the public of $3.50 per share. In connection with the offering, Cyclacel has granted the underwriters a 30-day option to purchase up to an additional 428,571 shares of common stock to cover over-allotments, if any. All of the shares of common stock in this offering are to be sold by Cyclacel.
Cyclacel Pharmaceuticals to offer common stock in public offering
M2 - Fri Apr 04, 5:21AM CDT
Biopharmaceutical company Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) said on Thursday that it plans to issue shares of its common stock in a public offering.
Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Apr 03, 3:21PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. The Company intends to use the net proceeds from this offering for funding the continued development of its most advanced product candidate, sapacitabine, in a randomized study of patients with myelodysplastic syndromes (MDS), and general corporate purposes. All of the shares in this offering are to be sold by Cyclacel. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Cyclacel Pharmaceuticals' net loss widens to USD19.5m in 2013
M2 - Wed Mar 26, 6:07AM CDT
US-based Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) disclosed on Tuesday a net loss of USD19.5m (USD1.28 per basic and diluted common share) for the year ended 31 December 2013.
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
European Expansion of SEAMLESS Phase 3 Study Initiated; Potentially Trebling Participating Sites
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 13, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce fourth quarter and full year 2013 financial results on Tuesday, March 25, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day.
Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company", a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 16th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, New York. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs on Monday, February 10, 2014 at 11:00 a.m. Eastern in the Duke of Windsor room.
Investors look to Lighten Up on Shares of Cyclacel Pharmaceuticals, Shares Down 6.2% (CYCC)
Comtex SmarTrend(R) - Mon Jan 27, 12:46PM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing low-priced stocks, down 6.2% to $3.60 on 1.4x average daily volume. Cyclacel Pharmaceuticals has traded 384,000 shares thus far today, vs. average volume of 284,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's -0.2%) and underperformed the S&P 500 (-6.2% to the S&P's -0.5%) during today's trading.
Ubiquiti inks distribution agreement with Ingram Micro
M2 - Thu Jan 16, 8:22AM CST
Ubiquiti Networks, Inc. (NASDAQ: UBNT) said it has announced a US distribution agreement with Ingram Micro Inc. (NYSE: IM).
Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014
GlobeNewswire - Mon Jan 13, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today reviewed 2013 achievements and provided an outline of the Company's key clinical development objectives for 2014, which will be highlighted at the Company's presentation during the Biotech Showcase(TM) 2014 Conference at 9:30 a.m. PST, Monday, Jan. 13, 2014, at the Parc 55 Wyndham Hotel - Union Square at 55 Cyril Magnin Street in San Francisco.
Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2014 Conference
GlobeNewswire - Mon Jan 06, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company", a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the Biotech Showcase 2014 conference being held at Parc 55 Wyndham San Francisco - Union Square at 55 Cyril Magnin Street, San Francisco, Calif. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 9:30 a.m. PST on Monday, January 13, 2014.
Cyclacel Pharmaceuticals Down 10.2%, Shares Slide into the Red (CYCC)
Comtex SmarTrend(R) - Mon Dec 09, 11:43AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing low-priced stocks, down 10.2% to $4.32 on 1.4x average daily volume. Thus far today, Cyclacel Pharmaceuticals has traded 487,000 shares, vs. average volume of 342,000 shares per day. The stock has underperformed the Dow (-10.2% to the Dow's 0.1%) and underperformed the S&P 500 (-10.2% to the S&P's 0.3%) during today's trading.
Cyclacel Reports New Phase 2 Data of Sapacitabine for MDS at ASH
GlobeNewswire - Mon Dec 09, 6:00AM CST
- Nearly Doubles Expected Median Survival of Older Patients with MDS after Treatment Failure of Hypomethylating Agents -
Cyclacel Pharmaceuticals Up 5.5%, Shares Break Through Resistance (CYCC)
Comtex SmarTrend(R) - Mon Nov 25, 10:28AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's best performing low-priced stocks, up 5.5% to $4.58 on 1.3x average daily volume. Thus far today, Cyclacel Pharmaceuticals has traded 391,000 shares, vs. average volume of 313,000 shares per day. The stock has outperformed the Dow (5.5% to the Dow's 0.2%) and outperformed the S&P 500 (5.5% to the S&P's 0.0%) during today's trading.
Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML
GlobeNewswire - Mon Nov 25, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 SEAMLESS study in acute myeloid leukemia (AML) has completed its third planned safety review and recommended that the study should continue as planned without any modifications. The DSMB reviewed available data from 212 randomized patients and noted that no safety or efficacy concerns were identified. The DSMB will conduct additional periodic reviews of each 100 patients and will also perform a futility assessment once half the required events have been observed.
Hot Stock: Cyclacel Pharmaceuticals, Shares Gain 6.4% (CYCC)
Comtex SmarTrend(R) - Thu Nov 14, 10:15AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's best performing low-priced stocks, up 6.4% to $4.16 on 1.4x average daily volume. Thus far today, Cyclacel Pharmaceuticals has traded 443,000 shares, vs. average volume of 318,000 shares per day. The stock has outperformed the Dow (6.4% to the Dow's 0.3%) and outperformed the S&P 500 (6.4% to the S&P's 0.3%) during today's trading.
Cyclacel Pharmaceuticals concludes offering of USD10m of common shares
M2 - Thu Apr 10, 7:01AM CDT
US-based biopharmaceutical company Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) revealed on Wednesday the completion of its offering of 2,857,143 shares of its common stock.
Independent Investigators Present Non-Clinical Data Providing Rationale for Sapacitabine Combination Treatment With Bcr-Abl Inhibitors in CML
GlobeNewswire - Thu Apr 10, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that independent investigators reported non-clinical data supporting the combination potential of Cyclacel's oral sapacitabine with Bcr-Abl inhibitors, including imatinib and ponatinib, in chronic myeloid leukemia (CML) cell lines. The data were reported in a poster presentation at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) held April 5-9, 2014 in San Diego.
Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering
GlobeNewswire - Wed Apr 09, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced that it has closed the previously announced underwritten offering of 2,857,143 shares of its common stock at a price to the public of $3.50 per share for gross proceeds of approximately $10.0 million. In addition, the Company has granted the underwriters a 30-day option to purchase an additional 428,571 shares of common stock to cover over-allotments, if any.
Cyclacel Pharmaceuticals Announces $10 Million Underwritten Offering
GlobeNewswire - Fri Apr 04, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced the pricing of an underwritten public offering of 2,857,143 shares of its common stock to institutional and other investors at a price to the public of $3.50 per share. In connection with the offering, Cyclacel has granted the underwriters a 30-day option to purchase up to an additional 428,571 shares of common stock to cover over-allotments, if any. All of the shares of common stock in this offering are to be sold by Cyclacel.
Cyclacel Pharmaceuticals to offer common stock in public offering
M2 - Fri Apr 04, 5:21AM CDT
Biopharmaceutical company Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) said on Thursday that it plans to issue shares of its common stock in a public offering.
Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Apr 03, 3:21PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. The Company intends to use the net proceeds from this offering for funding the continued development of its most advanced product candidate, sapacitabine, in a randomized study of patients with myelodysplastic syndromes (MDS), and general corporate purposes. All of the shares in this offering are to be sold by Cyclacel. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Cyclacel Pharmaceuticals' net loss widens to USD19.5m in 2013
M2 - Wed Mar 26, 6:07AM CDT
US-based Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) disclosed on Tuesday a net loss of USD19.5m (USD1.28 per basic and diluted common share) for the year ended 31 December 2013.
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
European Expansion of SEAMLESS Phase 3 Study Initiated; Potentially Trebling Participating Sites
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 13, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce fourth quarter and full year 2013 financial results on Tuesday, March 25, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day. Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 16th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, New York. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs on Monday, February 10, 2014 at 11:00 a.m. Eastern in the Duke of Windsor room. Investors look to Lighten Up on Shares of Cyclacel Pharmaceuticals, Shares Down 6.2% (CYCC)
Comtex SmarTrend(R) - Mon Jan 27, 12:46PM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing low-priced stocks, down 6.2% to $3.60 on 1.4x average daily volume. Cyclacel Pharmaceuticals has traded 384,000 shares thus far today, vs. average volume of 284,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's -0.2%) and underperformed the S&P 500 (-6.2% to the S&P's -0.5%) during today's trading.
Ubiquiti inks distribution agreement with Ingram Micro
M2 - Thu Jan 16, 8:22AM CST
Ubiquiti Networks, Inc. (NASDAQ: UBNT) said it has announced a US distribution agreement with Ingram Micro Inc. (NYSE: IM).
Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014
GlobeNewswire - Mon Jan 13, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today reviewed 2013 achievements and provided an outline of the Company's key clinical development objectives for 2014, which will be highlighted at the Company's presentation during the Biotech Showcase(TM) 2014 Conference at 9:30 a.m. PST, Monday, Jan. 13, 2014, at the Parc 55 Wyndham Hotel - Union Square at 55 Cyril Magnin Street in San Francisco.
Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2014 Conference
GlobeNewswire - Mon Jan 06, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the Biotech Showcase 2014 conference being held at Parc 55 Wyndham San Francisco - Union Square at 55 Cyril Magnin Street, San Francisco, Calif. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 9:30 a.m. PST on Monday, January 13, 2014. Cyclacel Pharmaceuticals Down 10.2%, Shares Slide into the Red (CYCC)
Comtex SmarTrend(R) - Mon Dec 09, 11:43AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing low-priced stocks, down 10.2% to $4.32 on 1.4x average daily volume. Thus far today, Cyclacel Pharmaceuticals has traded 487,000 shares, vs. average volume of 342,000 shares per day. The stock has underperformed the Dow (-10.2% to the Dow's 0.1%) and underperformed the S&P 500 (-10.2% to the S&P's 0.3%) during today's trading.
Cyclacel Reports New Phase 2 Data of Sapacitabine for MDS at ASH
GlobeNewswire - Mon Dec 09, 6:00AM CST
- Nearly Doubles Expected Median Survival of Older Patients with MDS after Treatment Failure of Hypomethylating Agents -
Cyclacel Pharmaceuticals Up 5.5%, Shares Break Through Resistance (CYCC)
Comtex SmarTrend(R) - Mon Nov 25, 10:28AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's best performing low-priced stocks, up 5.5% to $4.58 on 1.3x average daily volume. Thus far today, Cyclacel Pharmaceuticals has traded 391,000 shares, vs. average volume of 313,000 shares per day. The stock has outperformed the Dow (5.5% to the Dow's 0.2%) and outperformed the S&P 500 (5.5% to the S&P's 0.0%) during today's trading.
Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML
GlobeNewswire - Mon Nov 25, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 SEAMLESS study in acute myeloid leukemia (AML) has completed its third planned safety review and recommended that the study should continue as planned without any modifications. The DSMB reviewed available data from 212 randomized patients and noted that no safety or efficacy concerns were identified. The DSMB will conduct additional periodic reviews of each 100 patients and will also perform a futility assessment once half the required events have been observed.
Hot Stock: Cyclacel Pharmaceuticals, Shares Gain 6.4% (CYCC)
Comtex SmarTrend(R) - Thu Nov 14, 10:15AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's best performing low-priced stocks, up 6.4% to $4.16 on 1.4x average daily volume. Thus far today, Cyclacel Pharmaceuticals has traded 443,000 shares, vs. average volume of 318,000 shares per day. The stock has outperformed the Dow (6.4% to the Dow's 0.3%) and outperformed the S&P 500 (6.4% to the S&P's 0.3%) during today's trading.
